ZUG, Switzerland - Monday, 08. December 2025
L’Oréal to
acquire an additional 10% stake in Galderma recognizing its scientific
leadership in dermatology and long-term growth potential
Ad hoc announcement pursuant to Art. 53 LR
(BUSINESS
WIRE) -- Galderma Group AG (SIX:GALD), the pure-play dermatology
category leader, today announced that L’Oréal Groupe intends to increase
its equity investment in the company, acquiring an additional 10% stake
from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi
Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as
sellers).
Following the transaction, which is subject to
customary approvals, L’Oréal’s total shareholding in Galderma will rise
to 20%, building on its initial investment made in August 2024. The
transaction is expected to close in Q1 2026.
In connection with
this increased investment, Galderma will consider nominating two
non-independent board candidates from L’Oréal, replacing the board
members representing the consortium led by EQT, at the 2026 Annual
General Meeting.
Additionally, Galderma and L’Oréal aim at
exploring additional scientific research projects of mutual interest.
This ongoing collaboration brings together Galderma’s scientific
leadership in dermatology and L’Oréal’s expertise as the world’s leading
beauty player. With a shared focus on skincare and skin health,
innovation, and long-term growth, Galderma and L’Oréal are well
positioned in the fast-growing, consumer-focused dermatology and beauty
markets.
“Galderma continues to deliver
impressive growth, strong innovation and category leadership across its
broad, science-based dermatology portfolio. With strengthened commercial
execution, continued platform and portfolio expansion, and an
increasingly consumer-focused approach to innovation, we are rapidly
scaling into a dermatology powerhouse. We are pleased with L’Oréal’s
increased investment, which affirms our direction and the meaningful
value creation we expect in the years ahead. As we move into 2026, we
remain fully focused on our Integrated Dermatology Strategy and on
serving our customers, consumers, and patients.”
FLEMMING ØRNSKOV, M.D., MPH
CHIEF EXECUTIVE OFFICER
GALDERMA
About Galderma
Galderma
(SIX: GALD) is the pure-play dermatology category leader, present in
approximately 90 countries. We deliver an innovative, science-based
portfolio of premium flagship brands and services that span the full
spectrum of the fast-growing dermatology market through Injectable
Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since
our foundation in 1981, we have dedicated our focus and passion to the
human body’s largest organ – the skin – meeting individual consumer and
patient needs with superior outcomes in partnership with healthcare
professionals. Because we understand that the skin we are in shapes our
lives, we are advancing dermatology for every skin story. For more
information: www.galderma.com.
Forward-looking statements
Certain
statements in this announcement are forward-looking statements.
Forward-looking statements are statements that are not historical facts
and may be identified by words such as "plans", "targets", "aims", "
believes", "expects", "anticipates", "intends", "estimates", "will",
"may", "continues", "should" and similar expressions. These
forward-looking statements reflect, at the time, Galderma's beliefs,
intentions and current targets/ aims concerning, among other things,
Galderma's results of operations, financial condition, industry,
liquidity, prospects, growth and strategies and are subject to change.
The estimated financial information is based on management's current
expectations and is subject to change. By their nature, forward-looking
statements involve a number of risks, uncertainties and assumptions that
could cause actual results or events to differ materially from those
expressed or implied by the forward-looking statements. These risks,
uncertainties and assumptions could adversely affect the outcome and
financial consequences of the plans and events described herein. Actual
results may differ from those set forth in the forward-looking
statements as a result of various factors (including, but not limited
to, future global economic conditions, changed market conditions,
intense competition in the markets in which Galderma operates, costs of
compliance with applicable laws, regulations and standards, diverse
political, legal, economic and other conditions affecting Galderma’s
markets, and other factors beyond the control of Galderma). Neither
Galderma nor any of their respective shareholders (as applicable),
directors, officers, employees, advisors, or any other person is under
any obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise. You
should not place undue reliance on forward-looking statements, which
speak of the date of this announcement. Statements contained in this
announcement regarding past trends or events should not be taken as a
representation that such trends or events will continue in the future.
Some of the information presented herein is based on statements by third
parties, and no representation or warranty, express or implied, is made
as to, and no reliance should be placed on, the fairness,
reasonableness, accuracy, completeness or correctness of this
information or any other information or opinions contained herein, for
any purpose whatsoever. Except as required by applicable law, Galderma
has no intention or obligation to update, keep updated or revise this
announcement or any parts thereof.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251207921992/en/
Permalink
https://www.aetoswire.com/en/news/0812202551530
Contacts
For further information:
Media
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62
Investors
Emil Ivanov
Head of Strategy, Investor Relations and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43